LYCOS RETRIEVER 
Advair: Asthma
built 658 days ago
Advair is GlaxoSmithKline's biggest product, with $4 billion in sales during the first nine months of 2005. Serevent's sales were $450 million. Advair is a long-acting beta 2-adrenergic agonist, or LABA, which provides asthma relief by relaxing muscles around the airways to the lungs. Although they can reduce the number of asthma episodes, the FDA says they "may increase the chances of a severe asthma episode when they do occur."
Source:
Advair is a combination "controller" medicine for long-term treatment to prevent or decrease the symptoms of asthma and chronic lung diseases such as emphysema, bronchitis, or COPD. It works to open the airways of the lungs in two ways (decreasing bronchiolar swelling and causing muscle relaxation). It may ... be used to treat other breathing conditions as determined by your doctor. Advair does not work immediately and should not be used for acute asthma attacks. Use other "quick-relief" medicines/inhalers for sudden shortness of breath or asthma attacks.
Source:
Advair (fluticasone/salmeterol) is an inhaled medication used to treat asthma and COPD. It is a combination medication consisting of an inhaled steroid and a long-acting form of albuterol, called Serevent (salmeterol). The combination of these medications works especially well to control the inflammation in asthma. The salmeterol does not replace the need for rescue inhalers, such as albuterol, which are still needed for the immediate relief of asthma symptoms.
Source:
Advair is a blockbuster respiratory medication approved by the FDA in 2000 to treat the symptoms of asthma and chronic obstructive pulmonary disease. Advair combines two active medications to deliver effective treatment. Fluticasone is a steroid that reduces inflammation in the airways. Salmeterol is a long acting beta-2 agonist bronchodilator that relaxes and opens the airways to improve breathing.
Source:
Popular and long-acting asthma medicines such as Advair and Serevent pose a substantially increased risk of hospitalization and death to users compared with placebos, according to a new analysis of 19 studies on the subject. The analysis ... found that the increased risks of the long-acting bronchodilators affect a broad range of users more than doubling the rate at which asthma patients had to be hospitalized.
Source:
Advair represents the latest advance in asthma treatment. It improves lung function and provides excellent control of symptoms over 24 hours, helping asthmatics to live without nighttime awakenings, chest tightness, coughing and wheezing. Advair ... reduces the incidence of asthma attacks a patient may suffer from, as well as their need for rescue medications.
Source:
MORE ABOUT
Asthma